Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1977;55:375-378

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loeb, H. S.
Right arrow Articles by Gunner, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loeb, H. S.
Right arrow Articles by Gunner, R. M.

Circulation, Vol 55, 375-378, Copyright © 1977 by American Heart Association


ARTICLES

Superiority of dobutamine over dopamine for augmentation of cardiac output in patients with chronic low output cardiac failure

HS Loeb, J Bredakis and RM Gunner

Dobutamine is a newly developed catecholamine reported to have minimal direct vascular effects relative to its inotropic activity and to have less chronotropic and arrhythmogenic properties than other catecholamines used in the treatment of low output states. In this study, the acute hemodynamic effects of dobutamine were compared to those of dopamine in 13 patients with chronic low output cardiac failure. At dosages adjusted to achieve similar increments in cardiac output, dobutamine reduced left ventricular filling pressure (LVEP) from 24 +/- 2 mm Hg (SEM) to 17+/- 2 mm Hg, while dopamine increased LVEP to 30 +/- 3 mm Hg and in six patients caused arterial O2 saturation to fall below 90%. This poor response to dopamine was probably the result of its vasoconstrictive effects and illustrates the potential advantages of using a cardioselective agent such as dobutamine when the desired goal of therapy is to improve ventricular function by direct inotropic stimulation.


This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
H. Sakai, H. Kunichika, K. Murata, K. Seki, K. Katayama, T. Hiro, T. Miura, and M. Matsuzaki
Improvement of afterload mismatch of left atrial booster pump function with positive inotropic agent
J. Am. Coll. Cardiol., January 1, 2001; 37(1): 270 - 277.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
J. E. Naschitz, D. Yeshurun, and J. Shahar
Cardiogenic Hepatorenal Syndrome
Angiology, November 1, 1990; 41(11): 893 - 900.
[Abstract] [PDF]